Prices for brand-name drugs are typically higher in the U.S. than other developed countries. The drug industry has argued it's misleading to focus on U.S. list prices that exclude discounts struck behind closed doors with insurers.
A Bloomberg News analysis finds that even after these discounts, prices are higher in the U.S. than abroad. Seven of eight top-selling drugs examined still cost more in the U.S. than most other countries.
Bloomberg estimated the actual amounts that drug manufacturers are paid on a sample of top-selling drugs. SSR Health, an investment research firm, used prescription data and U.S. list prices to determine the drugs' sales in the country before discounts. To approximate the discounts, SSR Health subtracted the actual U.S. sales reported by the companies. Bloomberg compared the discounted monthly prices with list prices from 14 countries, using local data from IHS Inc., a data analysis and consulting firm, and other sources.
"We can no longer sustain a system where 300 million Americans subsidize drug development for the entire world," said Steve Miller, chief medical officer for Express Scripts Holding Co., the largest U.S. manager of prescription-drug benefits.
The drug industry sees it differently.
As marijuana use among teens has grown in the past decade, researchers have been trying to...
NYU Langone Health, one of New York City’s major hospital networks, announced this week that it...
